Latest Pacific Markets News

ReNerve Ltd (ASX:RNV) reported an 80% year-on-year revenue increase in Q4 FY26, backed by expanding product lines and a $5 million funding facility. The company is advancing FDA approvals and growing its global distribution footprint, targeting a rapidly expanding $6.19 billion nerve repair biomaterials market.

OpenLearning Limited posted a record $3.27 million in SaaS annual recurring revenue and its highest quarterly cash receipts of $1.653 million, driven by new multi-year contracts in the Philippines and Malaysia and launches of AI-driven student recruitment and employability platforms.

Island Pharmaceuticals has marked a major step forward in its antiviral program with the start of GMP manufacturing for Galidesivir, expanded USAMRIID collaboration, and FDA orphan drug designation. Regulatory approvals for compassionate use in Uganda’s Ebola outbreak and a new dose optimisation study with Texas Biomed further de-risk the pathway to approval.

ReNerve Limited delivered its strongest sales quarter ever with $211,000 in revenue, boosted by new distribution deals in Asia-Pacific and a $5 million funding facility to underpin growth.

NH3 Clean Energy (ASX:NH3) has updated investors on its WAH2 Project, aiming for commercial operations by 2030 to produce low-emissions ammonia for Asia-Pacific markets. The presentation highlights strategic advantages, partnerships, and a phased development plan amid ongoing contract and financing negotiations.

Orthocell Ltd delivered a standout FY26 with 44% revenue growth to A$13.2 million, powered by accelerating US sales of its nerve repair product Remplir and a robust cash position supporting further expansion.

ReNerve has locked in a flexible A$5 million convertible note facility with RiverFort, drawing an initial A$1.6 million to back its commercial push and US sales ramp-up.

SPC Global reported solid Q4 FY26 growth driven by domestic beverage sales and a 50.8% jump in international revenue, while a $100 million equity raise slashed net leverage and paved the way for improved cash flow in FY27.

HALO Technologies launches a convertible notes offer aiming to raise up to A$6.75 million, backing platform upgrades and expansion across Asia-Pacific and adviser networks.

Island Pharmaceuticals has strengthened its intellectual property portfolio with a Singapore patent covering ISLA-101 for flavivirus infections, including Dengue and Chikungunya, extending commercial exclusivity to 2034 in a key Asia-Pacific market.

SunRice reported a 4% rise in net profit after tax for FY26 to $73.3 million, maintaining an 8% EBITDA margin despite a 2.5% revenue decline. The company declared a record fully franked dividend of 70 cents per share but expects FY27 profit to fall amid a smaller Australian rice crop.

International Graphite Limited has inked a non-binding deal with Wogen Pacific to supply micronised graphite and feedstock for its Collie facility, targeting Asia-Pacific markets with an initial three-year term.